Announcements Trials
Browse Landscape

Phase

Phase 1/2 32Phase 2 21Phase 1 15Phase 3 5Phase 2/3 2Phase 4 1

Status

Recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 32INDUSTRY 5OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1Breast 1

Conditions

Carcinoma, Transitional Cell 2Triple Negative Breast Neoplasms 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1Cervical Cancer Metastatic 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × toripalimab × Clear all
NCT07362186 2026-05-11

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

LaNova Medicines Limited

Phase 3 Recruiting
400 enrolled

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Shanghai Jiatan Pharmatech Co., Ltd

Phase 3 Not yet recruiting
440 enrolled
Gynecologic

Cervical Cancer Metastatic

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
400 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06592326 2024-09-19

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 3 Recruiting
460 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

RemeGen Co., Ltd.

Phase 3 Recruiting
452 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡